AKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Akari Therapeutics Plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$9.89+1.71 (+20.90%)
Close on Oct 19, 2026
- Market cap
- $1.42T
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Akari Therapeutics has not reported a dividend
No dividend per share appears in Akari Therapeutics's annual filings since fiscal 2010.